Brokerages expect Inogen, Inc (NASDAQ:INGN) to report earnings per share of $0.29 for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Inogen’s earnings, with the lowest EPS estimate coming in at $0.24 and the highest estimate coming in at $0.33. Inogen reported earnings per share of $0.16 during the same quarter last year, which indicates a positive year-over-year growth rate of 81.3%. The company is expected to issue its next earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Inogen will report full year earnings of $1.20 per share for the current fiscal year, with EPS estimates ranging from $1.17 to $1.23. For the next financial year, analysts forecast that the business will post earnings of $1.30 per share, with EPS estimates ranging from $1.23 to $1.39. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Inogen.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.28 by $0.10. The company had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a return on equity of 12.45% and a net margin of 10.36%. Inogen’s revenue for the quarter was up 17.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.25 EPS.

Several research firms have recently commented on INGN. Piper Jaffray Companies reissued a “hold” rating and set a $90.00 target price on shares of Inogen in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $108.00 target price on shares of Inogen in a research report on Friday, September 1st. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, J P Morgan Chase & Co boosted their target price on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. Inogen currently has a consensus rating of “Buy” and an average target price of $91.33.

Shares of Inogen (NASDAQ INGN) traded down 2.00% during trading on Friday, hitting $101.52. The stock had a trading volume of 98,605 shares. The company has a market capitalization of $2.10 billion, a P/E ratio of 88.12 and a beta of 1.02. The firm has a 50-day moving average of $95.76 and a 200 day moving average of $87.16. Inogen has a 1-year low of $50.24 and a 1-year high of $104.88.

In other Inogen news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction dated Tuesday, July 18th. The shares were sold at an average price of $94.21, for a total value of $235,525.00. Following the completion of the sale, the executive vice president now directly owns 4,833 shares of the company’s stock, valued at approximately $455,316.93. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the sale, the director now directly owns 7,808 shares of the company’s stock, valued at $715,759.36. The disclosure for this sale can be found here. Insiders sold a total of 44,667 shares of company stock valued at $4,170,776 over the last ninety days. 5.31% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd bought a new stake in Inogen in the 2nd quarter worth about $442,000. Koch Industries Inc. grew its position in Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after purchasing an additional 653,747 shares in the last quarter. Verition Fund Management LLC bought a new stake in Inogen in the 2nd quarter worth about $280,000. Piedmont Investment Advisors LLC bought a new stake in Inogen in the 2nd quarter worth about $336,000. Finally, Ameritas Investment Partners Inc. grew its position in Inogen by 6.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,495 shares of the medical technology company’s stock worth $143,000 after purchasing an additional 86 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Anticipate Inogen, Inc (INGN) to Announce $0.29 EPS” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/15/zacks-brokerages-anticipate-inogen-inc-ingn-to-announce-0-29-eps.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Get a free copy of the Zacks research report on Inogen (INGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.